Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years

Aim: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and the immune persistence of a primary dose in 2- to 6-year-old children. Methods: A phase IV, open-label study was conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yukai, Wang, Lei, Wang, Yanxia, Zhang, Wei, Jia, Ningning, Xie, Zhiqiang, Huang, Lili, You, Wangyang, Lu, Weifeng, Li, Erwei, Gao, Feilong, Hu, Yuansheng, Meng, Fanhong, Xia, Shengli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146173/
https://www.ncbi.nlm.nih.gov/pubmed/35632416
http://dx.doi.org/10.3390/vaccines10050660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146173/
https://www.ncbi.nlm.nih.gov/pubmed/35632416
http://dx.doi.org/10.3390/vaccines10050660

Ejemplares similares